Keryx Biopharmaceuticals Inc (KERX)

NASDAQ
3.360
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    2.510/3.400
  • Day's Range:
    2.965 - 3.465

KERX Overview

Prev. Close
3.43
Day's Range
2.965-3.465
Revenue
94.22M
Open
3.44
52 wk Range
0-0
EPS
-0.76
Volume
0
Market Cap
343.98M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,499,882
P/E Ratio
-
Beta
2.12
1-Year Change
0%
Shares Outstanding
102,375,926
Next Earnings Date
-
What is your sentiment on Keryx Biopharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Keryx Biopharmaceuticals Inc News

  • Tricida readies IPO
    • BySeeking Alpha-

    South San Francisco, CA-based Tricida (TCDA) has filed a preliminary prospectus for a $150M IPO.The company says its goal is to slow the progression of chronic kidney disease (CKD)...

  • Premarket Losers as of 9:05 am
    • BySeeking Alpha-

    TLGT -37% on Q3 earnings.TRUE -32% on Q3 earnings.RRGB -22% on Q3 earnings.TEUM -22% on announcing pricing of $12M firm commitment public offering.VERI -20% on Q3 earnings.MNK -15%...

Keryx Biopharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell

Keryx Biopharmaceuticals Inc Company Profile

Keryx Biopharmaceuticals Inc Company Profile

Employees
189

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts. As of December 12, 2018, Keryx Biopharmaceuticals, Inc. operates as a subsidiary of Akebia Therapeutics, Inc.

Read More
  • Go Kerx Go Show me the money!!!! +40% now :)
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.